{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:28:09Z","timestamp":1793608089556,"version":"4.5.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["BC201356"],"award-info":[{"award-number":["BC201356"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 ES031796"],"award-info":[{"award-number":["R01 ES031796"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31 CA264889\\u201301A1"],"award-info":[{"award-number":["F31 CA264889\\u201301A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["DNA Repair"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.dnarep.2023.103563","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T03:34:40Z","timestamp":1692416080000},"page":"103563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond"],"prefix":"10.1016","volume":"130","author":[{"given":"Hayley L.","family":"Rein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dnarep.2023.103563_bib1","first-page":"862","article-title":"BRCA genes: BRCA 1 and BRCA 2","volume":"23","author":"Varol","year":"2018","journal-title":"J. BUON"},{"key":"10.1016\/j.dnarep.2023.103563_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.dnarep.2023.103563_bib3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.2270482","article-title":"Linkage of early-onset familial breast cancer to chromosome 17q21","volume":"250","author":"Hall","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.dnarep.2023.103563_bib4","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1126\/science.8091231","article-title":"Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13","volume":"265","author":"Wooster","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.dnarep.2023.103563_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103626","article-title":"BRCA1\/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: looking for the hidden meaning","volume":"172","author":"Fanale","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.dnarep.2023.103563_bib6","doi-asserted-by":"crossref","first-page":"8644","DOI":"10.1073\/pnas.151253498","article-title":"Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining","volume":"98","author":"Xia","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.dnarep.2023.103563_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.dnarep.2023.103563_bib8","doi-asserted-by":"crossref","first-page":"E5189","DOI":"10.1073\/pnas.1511585112","article-title":"Comparison of predicted and actual consequences of missense mutations","volume":"112","author":"Miosge","year":"2015","journal-title":"P Natl. Acad. Sci. USA"},{"key":"10.1016\/j.dnarep.2023.103563_bib9","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","article-title":"Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis","volume":"28","author":"Yoshida","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/bjd.13626","article-title":"Skin cancer risk in BRCA1\/2 mutation carriers","volume":"172","author":"Gumaste","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.dnarep.2023.103563_bib11","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","article-title":"Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D","volume":"112","author":"Yang","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.dnarep.2023.103563_bib12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/1471-2407-12-552","article-title":"Screening of finnish RAD51C founder mutations in prostate and colorectal cancer patients","volume":"12","author":"Pelttari","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10689-011-9426-1","article-title":"PALB2 mutations in familial breast and pancreatic cancer","volume":"10","author":"Hofstatter","year":"2011","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.trecan.2020.10.002","article-title":"PALB2 variants: protein domains and cancer susceptibility","volume":"7","author":"Nepomuceno","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","article-title":"Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2","volume":"22","author":"Xia","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.dnarep.2023.103563_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng1959","article-title":"PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene","volume":"39","author":"Rahman","year":"2007","journal-title":"Nat. Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/nar\/26.5.1179","article-title":"Isolation and characterization of RAD51C, a new human member of the RAD51 family of related genes","volume":"26","author":"Dosanjh","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.dnarep.2023.103563_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/geno.1998.5226","article-title":"Identification, characterization, and genetic mapping of Rad51d, a new mouse and human RAD51\/RecA-related gene","volume":"49","author":"Pittman","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.dnarep.2023.103563_bib20","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1101\/sqb.2017.82.035006","article-title":"Homologous recombination and replication fork protection: BRCA2 and more!","volume":"82","author":"Feng","year":"2017","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib22","doi-asserted-by":"crossref","first-page":"12871","DOI":"10.1073\/pnas.2135498100","article-title":"Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer","volume":"100","author":"Vilenchik","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.dnarep.2023.103563_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.dnarep.2023.103563_bib24","doi-asserted-by":"crossref","first-page":"a016600","DOI":"10.1101\/cshperspect.a016600","article-title":"Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins","volume":"7","author":"Prakash","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib25","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/onc.2013.421","article-title":"Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair","volume":"33","author":"Park","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.dnarep.2023.103563_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/MCB.00465-12","article-title":"Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway","volume":"33","author":"Chun","year":"2013","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib27","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1139\/bcb-2016-0012","article-title":"Novel insights into RAD51 activity and regulation during homologous recombination and DNA replication","volume":"94","author":"Godin","year":"2016","journal-title":"Biochem Cell Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib28","doi-asserted-by":"crossref","first-page":"10328","DOI":"10.1073\/pnas.0604232103","article-title":"Origins and evolution of the recA\/RAD51 gene family: evidence for ancient gene duplication and endosymbiotic gene transfer","volume":"103","author":"Lin","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.dnarep.2023.103563_bib29","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1101\/gad.947001","article-title":"Identification and purification of two distinct complexes containing the five RAD51 paralogs","volume":"15","author":"Masson","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.dnarep.2023.103563_bib30","doi-asserted-by":"crossref","first-page":"29100","DOI":"10.1074\/jbc.M002075200","article-title":"The RAD51 family member, RAD51L3, is a DNA-stimulated ATPase that forms a complex with XRCC2","volume":"275","author":"Braybrooke","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.dnarep.2023.103563_bib31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes - association analysis in more than 113,000 women","volume":"384","author":"Breast Cancer Association","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.dnarep.2023.103563_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13048-020-00654-3","article-title":"BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of \u223c30,000 cases","volume":"13","author":"Suszynska","year":"2020","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.dnarep.2023.103563_bib33","first-page":"9835","article-title":"Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart","volume":"43","author":"Somyajit","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib34","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1101\/gad.336446.120","article-title":"Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand cross-links","volume":"34","author":"Rickman","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.dnarep.2023.103563_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.880643","article-title":"Homologous recombination deficiency in ovarian, breast, colorectal, pancreatic, non-small cell lung and prostate cancers, and the mechanisms of resistance to PARP inhibitors","volume":"12","author":"Mekonnen","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.dnarep.2023.103563_bib36","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.dnarep.2023.103563_bib38","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.dnarep.2023.103563_bib39","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population","volume":"33","author":"Song","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.dnarep.2023.103563_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.trecan.2019.11.006","article-title":"Evolving significance of tumor-normal sequencing in cancer care","volume":"6","author":"Mandelker","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa044383","article-title":"Benign breast disease and the risk of breast cancer","volume":"353","author":"Hartmann","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.dnarep.2023.103563_bib42","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1006\/gyno.1994.1334","article-title":"Characteristics relating to ovarian cancer risk: implications for prevention and detection","volume":"55","author":"Whittemore","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.dnarep.2023.103563_bib43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s42003-020-01301-9","article-title":"Genetic and clinical landscape of breast cancers with germline BRCA1\/2 variants","volume":"3","author":"Inagaki-Kawata","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.dnarep.2023.103563_bib45","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1093\/hmg\/ddr229","article-title":"RAD51C is a susceptibility gene for ovarian cancer","volume":"20","author":"Pelttari","year":"2011","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41523-019-0115-9","article-title":"Homologous recombination DNA repair defects in PALB2-associated breast cancers","volume":"5","author":"Li","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib47","article-title":"Utility of homologous recombination deficiency biomarkers across cancer types","volume":"6","author":"Takamatsu","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.dnarep.2023.103563_bib48","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","article-title":"Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer","volume":"11","author":"Chopra","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.dnarep.2023.103563_bib49","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.dnarep.2023.103563_bib50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.dnarep.2023.103563_bib51","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.dnarep.2023.103563_bib52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10689-014-9747-y","article-title":"Identification of a breast cancer family double heterozygote for RAD51C and BRCA2 gene mutations","volume":"14","author":"Ahlborn","year":"2015","journal-title":"Fam. Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib53","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.3892\/ol.2015.3123","article-title":"Double PALB2 and BRCA1\/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population","volume":"9","author":"Ancot","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.dnarep.2023.103563_bib54","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13058-016-0768-3","article-title":"Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women","volume":"18","author":"Rebbeck","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/jmedgenet-2018-105606","article-title":"Screening of BRCA1\/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast\/ovarian cancer","volume":"56","author":"Montalban","year":"2019","journal-title":"J. Med Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/path.5839","article-title":"Splicing predictions, minigene analyses, and ACMG-AMP clinical classification of 42 germline PALB2 splice-site variants","volume":"256","author":"Valenzuela-Palomo","year":"2022","journal-title":"J. Pathol."},{"key":"10.1016\/j.dnarep.2023.103563_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112845","article-title":"RAD51D aberrant splicing in breast cancer: identification of splicing regulatory elements and minigene-based evaluation of 53 DNA variants","volume":"13","author":"Bueno-Martinez","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.dnarep.2023.103563_bib58","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nature09399","article-title":"Purified human BRCA2 stimulates RAD51-mediated recombination","volume":"467","author":"Jensen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.dnarep.2023.103563_bib59","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.79183","article-title":"BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair","volume":"11","author":"Jimenez-Sainz","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.dnarep.2023.103563_bib60","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nsb1001-833","article-title":"Structure of a BRCA1-BARD1 heterodimeric RING-RING complex","volume":"8","author":"Brzovic","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib61","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/nsb1001-838","article-title":"Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1","volume":"8","author":"Williams","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1701386","article-title":"Structural analysis of BRCA1 reveals modification hotspot","volume":"3","author":"Liang","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.dnarep.2023.103563_bib63","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"key":"10.1016\/j.dnarep.2023.103563_bib64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13073-019-0690-2","article-title":"G. Clinical Genome Resource Sequence Variant Interpretation Working, Recommendations for application of the functional evidence PS3\/BS3 criterion using the ACMG\/AMP sequence variant interpretation framework","volume":"12","author":"Brnich","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.dnarep.2023.103563_bib65","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ajhg.2022.10.013","article-title":"G. ClinGen Sequence Variant Interpretation Working, Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3\/BP4 criteria","volume":"109","author":"Pejaver","year":"2022","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib66","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/humu.23626","article-title":"G. ClinGen Sequence Variant Interpretation Working, Recommendations for interpreting the loss of function PVS1 ACMG\/AMP variant criterion","volume":"39","author":"Abou Tayoun","year":"2018","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.dnarep.2023.103563_bib67","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/gim.2017.210","article-title":"G. ClinGen sequence variant interpretation working, modeling the ACMG\/AMP variant classification guidelines as a Bayesian classification framework","volume":"20","author":"Tavtigian","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.dnarep.2023.103563_bib68","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/humu.21628","article-title":"Enigma, ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes","volume":"33","author":"Spurdle","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.dnarep.2023.103563_bib69","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.dnarep.2023.103563_bib70","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.dnarep.2023.103563_bib71","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/humu.23644","article-title":"A. Clinical Genome Resource, G. Diversity Working, The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomics","volume":"39","author":"Popejoy","year":"2018","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.dnarep.2023.103563_bib72","doi-asserted-by":"crossref","unstructured":"US Preventative Services Task Force, D.K. Owens, K.W. Davidson, A.H. Krist, M.J. Barry, M. Cabana, A.B. Caughey, C.A. Doubeni, J.W. Epling Jr., M. Kubik, C.S. Landefeld, C.M. Mangione, L. Pbert, M. Silverstein, M.A. Simon, C.W. Tseng, J.B. Wong, Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement, JAMA 322 (2019) 652\u2013665.","DOI":"10.1001\/jama.2019.10987"},{"key":"10.1016\/j.dnarep.2023.103563_bib73","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3892\/or.2014.3685","article-title":"A novel PALB2 truncating mutation in an Italian family with male breast cancer","volume":"33","author":"Vietri","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.dnarep.2023.103563_bib74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/CEJ.0000000000000240","article-title":"The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer","volume":"26","author":"Neidhardt","year":"2017","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.dnarep.2023.103563_bib75","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12282-016-0693-4","article-title":"Family history predictors of BRCA1\/BRCA2 mutation status among Tunisian breast\/ovarian cancer families","volume":"24","author":"Riahi","year":"2017","journal-title":"Breast Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib76","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10549-020-06066-7","article-title":"The RAD51D c.82G>A (p.Val28Met) variant disrupts normal splicing and is associated with hereditary ovarian cancer","volume":"185","author":"Yang","year":"2021","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.dnarep.2023.103563_bib77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4132\/jptm.2022.05.02","article-title":"Founder BRCA1 mutations in Nepalese population","volume":"56","author":"Mehta","year":"2022","journal-title":"J. Pathol. Transl. Med"},{"issue":"Suppl 6","key":"10.1016\/j.dnarep.2023.103563_bib78","doi-asserted-by":"crossref","first-page":"vi93","DOI":"10.1093\/annonc\/mdm234","article-title":"Founder mutations in BRCA1 and BRCA2 genes","volume":"18","author":"Ferla","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.dnarep.2023.103563_bib79","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cancergen.2022.05.042","article-title":"Discovery of BRCA1\/BRCA2 founder variants by haplotype analysis","volume":"266\u2013267","author":"Kwon","year":"2022","journal-title":"Cancer Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib80","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41436-020-0920-4","article-title":"Considerations in assessing germline variant pathogenicity using cosegregation analysis","volume":"22","author":"Belman","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.dnarep.2023.103563_bib81","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.molcel.2015.07.009","article-title":"A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination","volume":"59","author":"Wang","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.dnarep.2023.103563_bib82","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1038\/ncomms9829","article-title":"A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51","volume":"6","author":"Ameziane","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.dnarep.2023.103563_bib83","article-title":"A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect","volume":"8","author":"Dawson","year":"2020","journal-title":"Mol. Genet Genom. Med"},{"key":"10.1016\/j.dnarep.2023.103563_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2021.104260","article-title":"A homozygous nonsense mutation early in exon 5 of BRCA2 is associated with very severe Fanconi anemia","volume":"64","author":"Radulovic","year":"2021","journal-title":"Eur. J. Med Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib85","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41523-021-00322-9","article-title":"Clinical consequences of BRCA2 hypomorphism","volume":"7","author":"Castells-Roca","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib86","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ajhg.2016.03.024","article-title":"Performance of ACMG-AMP variant-interpretation guidelines among nine laboratories in the clinical sequencing exploratory research consortium","volume":"98","author":"Amendola","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.dnarep.2023.103563_bib87","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.gim.2021.11.018","article-title":"Evaluating the impact of in silico predictors on clinical variant classification","volume":"24","author":"Wilcox","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.dnarep.2023.103563_bib88","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13059-017-1353-5","article-title":"Evaluation of in silico algorithms for use with ACMG\/AMP clinical variant interpretation guidelines","volume":"18","author":"Ghosh","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib89","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","article-title":"REVEL: an ensemble method for predicting the pathogenicity of rare missense variants","volume":"99","author":"Ioannidis","year":"2016","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib90","doi-asserted-by":"crossref","first-page":"12752","DOI":"10.1038\/s41598-019-49224-8","article-title":"REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification","volume":"9","author":"Tian","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.dnarep.2023.103563_bib91","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202727119","article-title":"Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants","volume":"119","author":"Prakash","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.dnarep.2023.103563_bib92","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41586-021-04043-8","article-title":"Disease variant prediction with deep generative models of evolutionary data","volume":"599","author":"Frazer","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.dnarep.2023.103563_bib93","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41436-019-0682-z","article-title":"Functional characterization of 84 PALB2 variants of uncertain significance","volume":"22","author":"Wiltshire","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.dnarep.2023.103563_bib94","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-22-2319","article-title":"Functional and clinical characterization of variants of uncertain significance identifies a hotspot for inactivating missense variants in RAD51C","author":"Hu","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib95","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s12885-023-10790-w","article-title":"Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays","volume":"23","author":"Bassi","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib96","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-20-0255","article-title":"Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays","volume":"26","author":"Bouwman","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib97","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1038\/s41388-022-02363-1","article-title":"Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests","volume":"41","author":"Meijer","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.dnarep.2023.103563_bib98","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA Repair inhibitor response in short-term patient-derived ovarian cancer organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.dnarep.2023.103563_bib99","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1101\/gad.13.20.2633","article-title":"XRCC3 promotes homology-directed repair of DNA damage in mammalian cells","volume":"13","author":"Pierce","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.dnarep.2023.103563_bib100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.dnarep.2004.08.010","article-title":"Molecular analysis of sister chromatid recombination in mammalian cells","volume":"4","author":"Puget","year":"2005","journal-title":"DNA Repair (Amst. )"},{"key":"10.1016\/j.dnarep.2023.103563_bib101","doi-asserted-by":"crossref","first-page":"9379","DOI":"10.1093\/nar\/gkv993","article-title":"Nuclear domain 'knock-in' screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing","volume":"43","author":"Pinder","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib102","doi-asserted-by":"crossref","first-page":"9658","DOI":"10.1158\/0008-5472.CAN-07-0290","article-title":"RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors","volume":"67","author":"Martin","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib103","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/1541-7786.MCR-10-0451","article-title":"The homologous recombination protein RAD51D mediates the processing of 6-thioguanine lesions downstream of mismatch repair","volume":"9","author":"Rajesh","year":"2011","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib104","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1182\/blood-2010-12-324541","article-title":"A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay","volume":"118","author":"Biswas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.dnarep.2023.103563_bib105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-60761-759-4_16","article-title":"Functional analysis of human BRCA2 variants using a mouse embryonic stem cell-based assay","volume":"653","author":"Kuznetsov","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib106","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1038\/s41467-019-13194-2","article-title":"Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2","volume":"10","author":"Boonen","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.dnarep.2023.103563_bib107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008355","article-title":"Differential Requirements for the RAD51 Paralogs in Genome Repair and Maintenance in Human Cells","volume":"15","author":"Garcin","year":"2019","journal-title":"PLoS Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib108","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.dnarep.2023.103563_bib109","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1016\/j.molcel.2021.07.015","article-title":"Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency","volume":"81","author":"Cong","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.dnarep.2023.103563_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23074049","article-title":"Validation and Data-Integration of Yeast-Based Assays for Functional Classification of BRCA1 Missense Variants","volume":"23","author":"Belle","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.dnarep.2023.103563_bib111","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.genet.38.072902.091500","article-title":"Recombination proteins in yeast","volume":"38","author":"Krogh","year":"2004","journal-title":"Annu Rev. Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib112","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/embor.2011.99","article-title":"A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance","volume":"12","author":"Menzel","year":"2011","journal-title":"EMBO Rep."},{"key":"10.1016\/j.dnarep.2023.103563_bib113","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1101\/sqb.2017.82.034413","article-title":"Fork protection and therapy resistance in hereditary breast cancer","volume":"82","author":"Cantor","year":"2017","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib114","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1363-4","article-title":"Isomerization of BRCA1-BARD1 promotes replication fork protection","volume":"571","author":"Daza-Martin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.dnarep.2023.103563_bib115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/(SICI)1526-968X(200003)26:3<167::AID-GENE1>3.0.CO;2-M","article-title":"Midgestation lethality in mice deficient for the RecA-related gene, Rad51d\/Rad51l3","volume":"26","author":"Pittman","year":"2000","journal-title":"Genesis"},{"key":"10.1016\/j.dnarep.2023.103563_bib116","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-08-3057","article-title":"Loss of Rad51c leads to embryonic lethality and modulation of Trp53-dependent tumorigenesis in mice","volume":"69","author":"Kuznetsov","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib117","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/hmg\/ddq207","article-title":"Inactivation of Palb2 gene leads to mesoderm differentiation defect and early embryonic lethality in mice","volume":"19","author":"Rantakari","year":"2010","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib118","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/386804a0","article-title":"Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2","volume":"386","author":"Sharan","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.dnarep.2023.103563_bib119","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ng0296-191","article-title":"Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities","volume":"12","author":"Gowen","year":"1996","journal-title":"Nat. Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nature13695","article-title":"Saturation editing of genomic regions by multiplex homology-directed repair","volume":"513","author":"Findlay","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.dnarep.2023.103563_bib121","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","article-title":"Accurate classification of BRCA1 variants with saturation genome editing","volume":"562","author":"Findlay","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.dnarep.2023.103563_bib122","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.ajhg.2021.11.001","article-title":"Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TP53, and PTEN","volume":"108","author":"Fayer","year":"2021","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib123","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1534\/genetics.115.175802","article-title":"Massively Parallel Functional Analysis of BRCA1 RING Domain Variants","volume":"200","author":"Starita","year":"2015","journal-title":"Genetics"},{"key":"10.1016\/j.dnarep.2023.103563_bib124","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/hmg\/ddi476","article-title":"Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility","volume":"15","author":"Morris","year":"2006","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib125","doi-asserted-by":"crossref","first-page":"8457","DOI":"10.1128\/MCB.24.19.8457-8466.2004","article-title":"BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number","volume":"24","author":"Starita","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib126","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1038\/sj.onc.1210968","article-title":"A CRM1-mediated nuclear export signal governs cytoplasmic localization of BRCA2 and is essential for centrosomal localization of BRCA2","volume":"27","author":"Han","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.dnarep.2023.103563_bib127","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/onc.2011.271","article-title":"Functional differences among BRCA1 missense mutations in the control of centrosome duplication","volume":"31","author":"Kais","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.dnarep.2023.103563_bib128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/0008-5472.417.65.2","article-title":"Functional evaluation and cancer risk assessment of BRCA2 unclassified variants","volume":"65","author":"Wu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.dnarep.2023.103563_bib129","first-page":"122","article-title":"Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study","volume":"59","author":"Gaba","year":"2022","journal-title":"J. Med Genet"},{"key":"10.1016\/j.dnarep.2023.103563_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061494","article-title":"Impact of BRCA Status on Reproductive Decision-Making and Self-Concept: A Mixed-Methods Study Informing the Development of Tailored Interventions","volume":"14","author":"Hesse-Biber","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dnarep.2023.103563_bib131","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/1471-0528.15905","article-title":"Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes","volume":"127","author":"Manchanda","year":"2020","journal-title":"BJOG"},{"key":"10.1016\/j.dnarep.2023.103563_bib132","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/bjc.2012.599","article-title":"Short-term psychological impact of the BRCA1\/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer","volume":"108","author":"Bredart","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib133","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.chembiol.2017.08.027","article-title":"Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy","volume":"24","author":"Hengel","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.dnarep.2023.103563_bib134","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.molcel.2022.04.023","article-title":"Exploiting replication gaps for cancer therapy","volume":"82","author":"Cong","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.dnarep.2023.103563_bib135","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Poltheta inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.dnarep.2023.103563_bib136","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1016\/j.molcel.2022.09.013","article-title":"POLtheta prevents MRE11-NBS1-CtIP-dependent fork breakage in the absence of BRCA2\/RAD51 by filling lagging-strand gaps","volume":"82","author":"Mann","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.dnarep.2023.103563_bib137","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.aar5149","article-title":"Beyond PARP-POLtheta as an anticancer target","volume":"359","author":"Higgins","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.dnarep.2023.103563_bib138","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.dnarep.2023.103563_bib139","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1016\/j.molcel.2021.08.016","article-title":"REV1-Polzeta maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps","volume":"81","author":"Taglialatela","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.dnarep.2023.103563_bib140","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","article-title":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","volume":"7","author":"Quigley","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.dnarep.2023.103563_bib141","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.dnarep.2023.103563_bib142","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/2159-8290.CD-17-0734","article-title":"Reversion mutations with clinical use of PARP inhibitors: many genes, many versions","volume":"7","author":"Domchek","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.dnarep.2023.103563_bib143","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006083","article-title":"Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation","volume":"7","author":"Sullivan","year":"2021","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.dnarep.2023.103563_bib144","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"}],"container-title":["DNA Repair"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568786423001179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568786423001179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:09:29Z","timestamp":1778821769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568786423001179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":143,"alternative-id":["S1568786423001179"],"URL":"https:\/\/doi.org\/10.1016\/j.dnarep.2023.103563","relation":{},"ISSN":["1568-7864"],"issn-type":[{"value":"1568-7864","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finding significance: New perspectives in variant classification of the RAD51 regulators, BRCA2 and beyond","name":"articletitle","label":"Article Title"},{"value":"DNA Repair","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dnarep.2023.103563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103563"}}